These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
286 related articles for article (PubMed ID: 25979073)
1. Plasma Kallikrein-Kinin System as a VEGF-Independent Mediator of Diabetic Macular Edema. Kita T; Clermont AC; Murugesan N; Zhou Q; Fujisawa K; Ishibashi T; Aiello LP; Feener EP Diabetes; 2015 Oct; 64(10):3588-99. PubMed ID: 25979073 [TBL] [Abstract][Full Text] [Related]
2. Kallikrein-Kinin System: An Emerging Competitor or Collaborator for VEGF in Diabetic Macular Edema? Murakami T Diabetes; 2015 Oct; 64(10):3350-2. PubMed ID: 26405275 [No Abstract] [Full Text] [Related]
3. The Role of Plasma Kallikrein-Kinin Pathway in the Development of Diabetic Retinopathy: Pathophysiology and Therapeutic Approaches. Abdulaal M; Haddad NM; Sun JK; Silva PS Semin Ophthalmol; 2016; 31(1-2):19-24. PubMed ID: 26959125 [TBL] [Abstract][Full Text] [Related]
6. Targeting the kallikrein-kinin system as a new therapeutic approach to diabetic retinopathy. Pruneau D; Bélichard P; Sahel JA; Combal JP Curr Opin Investig Drugs; 2010 May; 11(5):507-14. PubMed ID: 20419596 [TBL] [Abstract][Full Text] [Related]
7. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Funatsu H; Yamashita H; Sakata K; Noma H; Mimura T; Suzuki M; Eguchi S; Hori S Ophthalmology; 2005 May; 112(5):806-16. PubMed ID: 15878060 [TBL] [Abstract][Full Text] [Related]
8. Vitreous levels of interleukin-6 and vascular endothelial growth factor are related to diabetic macular edema. Funatsu H; Yamashita H; Ikeda T; Mimura T; Eguchi S; Hori S Ophthalmology; 2003 Sep; 110(9):1690-6. PubMed ID: 13129863 [TBL] [Abstract][Full Text] [Related]
9. Kallikrein-kinin activation by altered vitreous pH: New perspectives for treatment and pathogenesis of diabetic macular edema? : Comment on: Gao BB et al. Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med. 2007 Feb;13(2):181-8. Zeitz O; Keserü M Graefes Arch Clin Exp Ophthalmol; 2007 Dec; 245(12):1745-7. PubMed ID: 17823811 [TBL] [Abstract][Full Text] [Related]
10. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcinolone. Brooks HL; Caballero S; Newell CK; Steinmetz RL; Watson D; Segal MS; Harrison JK; Scott EW; Grant MB Arch Ophthalmol; 2004 Dec; 122(12):1801-7. PubMed ID: 15596583 [TBL] [Abstract][Full Text] [Related]
11. Concentration gradient of vascular endothelial growth factor in the vitreous of eyes with diabetic macular edema. Shimada H; Akaza E; Yuzawa M; Kawashima M Invest Ophthalmol Vis Sci; 2009 Jun; 50(6):2953-5. PubMed ID: 19060271 [TBL] [Abstract][Full Text] [Related]
12. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Funatsu H; Yamashita H; Ikeda T; Nakanishi Y; Kitano S; Hori S Am J Ophthalmol; 2002 Apr; 133(4):537-43. PubMed ID: 11931788 [TBL] [Abstract][Full Text] [Related]
18. The kallikrein-kinin system in diabetic retinopathy. Bhat M; Pouliot M; Couture R; Vaucher E Prog Drug Res; 2014; 69():111-43. PubMed ID: 25130041 [TBL] [Abstract][Full Text] [Related]
19. Diabetic macular edema. Lang GE Ophthalmologica; 2012; 227 Suppl 1():21-9. PubMed ID: 22517122 [TBL] [Abstract][Full Text] [Related]
20. Investigational plasma kallikrein inhibitors for the treatment of diabetic macular edema: an expert assessment. Bhatwadekar AD; Kansara VS; Ciulla TA Expert Opin Investig Drugs; 2020 Mar; 29(3):237-244. PubMed ID: 31985300 [No Abstract] [Full Text] [Related] [Next] [New Search]